Physician profile
Matthew Wolf
NPI 1043292022
$573.80
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $68.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $112.67 | 2019 | |
| Novo Nordisk INC | $103.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.68 | 2019-2020 | |
| Amgen INC. | $64.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.30 | 2019 | |
| Ironshore Pharmaceuticals INC. | $29.29 | 2019 | |
| Allergan, INC. | $21.99 | 2020 | |
| Arbor Pharmaceuticals, INC. | $20.80 | 2020 | |
| Tris Pharma INC | $16.41 | 2019 | |
| Radius Health, INC. | $13.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.12 | 2019 | |
| Sanofi Pasteur INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.